A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes

Molecular Therapy

Volumn 18, Issue 9, 2010, Pages 1606-1614

  Sun, Dongmei ^a   Zhuang, Xiaoying ^b,c   Xiang, Xiaoyu ^b,c   Liu, Yuelong ^c   Zhang, Shuangyin ^c   Liu, Cunren ^c   Barnes, Stephen ^d   Grizzle, William ^e   Miller, Donald ^b   Zhang, Huang Ge ^b,c,f,g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c The University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

^g University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; LIPOPOLYSACCHARIDE; LIPOSOME; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG STABILITY; DRUG TARGETING; EXOSOME; FEMALE; INFLAMMATORY CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; SEPTIC SHOCK;

EID: 77956264919     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.105     Document Type: Article

References (50)

1. Iwamoto, S, Iwai, S, Tsujiyama, K, Kurahashi, C, Takeshita, K, Naoe, M et al. (2007). TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol 179: 1449-1457.
2. Jongstra-Bilen, J, Haidari, M, Zhu, SN, Chen, M, Guha, D and Cybulsky, MI (2006). Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 203: 2073-2083.
3. Xu, H, Manivannan, A, Dawson, R, Crane, IJ, Mack, M, Sharp, P et al. (2005). Differentiation to the CCR2+ inflammatory phenotype in vivo is a constitutive, time-limited property of blood monocytes and is independent of local inflammatory mediators. J Immunol 175: 6915-6923.
4. Taylor, EL, Megson, IL, Haslett, C and Rossi, AG (2003). Nitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ 10: 418-430.
5. Chen, K, Huang, J, Liu, Y, Gong, W, Cui, Y and Wang, JM (2009). Synergy of TRIF-dependent TLR3 and MyD88-dependent TLR7 in up-regulating expression of mouse FPR2, a promiscuous G-protein-coupled receptor, in microglial cells. J Neuroimmunol 213: 69-77.
6. Pais, TF, Figueiredo, C, Peixoto, R, Braz, MH and Chatterjee, S (2008). Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway. J Neuroinflammation 5: 43.
7. Sasahara, M, Otani, A, Oishi, A, Kojima, H, Yodoi, Y, Kameda, T et al. (2008). Activation of bone marrow-derived microglia promotes photoreceptor survival in inherited retinal degeneration. Am J Pathol 172: 1693-1703.
8. Croce, K, Gao, H, Wang, Y, Mooroka, T, Sakuma, M, Shi, C et al. (2009). Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 120: 427-436.
9. Soehnlein, O and Weber, C (2009). Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol 31: 35-47.
10. Nygren, JM, Liuba, K, Breitbach, M, Stott, S, Thorén, L, Roell, W et al. (2008). Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiationinduced heterotypic cell fusion. Naion. Nat Cell Biol 10: 584-592.
11. Boyd, JH, Kan, B, Roberts, H, Wang, Y and Walley, KR (2008). S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102: 1239-1246.
12. Beekhuizen, H, Blokland, I, Corsèl-van Tilburg, AJ, Koning, F and van Furth, R (1991). CD14 contributes to the adherence of human monocytes to cytokine-stimulated endothelial cells. J Immunol 147: 3761-3767.
13. Qu, P, Du, H, Li, Y and Yan, C (2009). Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung. J Immunol 182: 1648-1659.
14. Medoff, BD, Seung, E, Hong, S, Thomas, SY, Sandall, BP, Duffield, JS et al. (2009). CD11b+ myeloid cells are the key mediators of Th2 cell homing into the airway in allergic inflammation. J Immunol 182: 623-635.
15. Deng, ZB, Liu, Y, Liu, C, Xiang, X, Wang, J, Cheng, Z et al. (2009). Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 50: 1412-1420.
16. Strom, SS, Yamamura, Y, Kantarijian, HM and Cortes-Franco, JE (2009). Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 18: 1501-1506.
17. Nguyen, MT, Favelyukis, S, Nguyen, AK, Reichart, D, Scott, PA, Jenn, A et al. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 282: 35279-35292.
18. Tzima, S, Victoratos, P, Kranidioti, K, Alexiou, M and Kollias, G (2009). Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. J Exp Med 206: 1167-1179.
19. King, IL, Dickendesher, TL and Segal, BM (2009). Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113: 3190-3197.
20. Dominguez-Soto, A and Corbi, AL (2007). Myeloid dendritic cell lectins and their role in immune responses. Curr Opin Investig Drugs 8: 910-920.
21. Zhu, B, Bando, Y, Xiao, S, Yang, K, Anderson, AC, Kuchroo, VK et al. (2007). CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179: 5228-5237.
22. McKinlay, A, Radford, K, Kato, M, Field, K, Gardiner, D, Khalil, D et al. (2007). Blood monocytes, myeloid dendritic cells and the cytokines interleukin (IL)-7 and IL-15 maintain human CD4+ T memory cells with mixed helper/regulatory function. Immunology 120: 392-403.
23. Ostrand-Rosenberg, S and Sinha, P (2009). Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
24. Gonzalez-Mejia, ME and Doseff, AI (2009). Regulation of monocytes and macrophages cell fate. Front Biosci 14: 2413-2431.
25. Bunt, SK, Clements, VK, Hanson, EM, Sinha, P and Ostrand-Rosenberg, S (2009). Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through toll-like receptor 4. J Leukoc Biol 85: 996-1004.
26. Gabrilovich, DI and Nagaraj, S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
27. Sinha, P, Clements, VK, Fulton, AM and Ostrand-Rosenberg, S (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507-4513.
28. Bunt, SK, Sinha, P, Clements, VK, Leips, J and Ostrand-Rosenberg, S (2006). Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176: 284-290.
29. Xiang, X, Poliakov, A, Liu, C, Liu, Y, Deng, ZB, Wang, J et al. (2009). Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 124: 2621-2633.
30. Iero, M, Valenti, R, Huber, V, Filipazzi, P, Parmiani, G, Fais, S et al. (2008). Tumourreleased exosomes and their implications in cancer immunity. Cell Death Differ 15: 80-88.
31. Bhatnagar, S, Shinagawa, K, Castellino, FJ and Schorey, JS (2007). Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 110: 3234-3244.
32. Yu, S, Liu, C, Su, K, Wang, J, Liu, Y, Zhang, L et al. (2007). Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178: 6867-6875.
33. Valenti, R, Huber, V, Iero, M, Filipazzi, P, Parmiani, G and Rivoltini, L (2007). Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67: 2912-2915
34. Ravindran, J, Prasad, S and Aggarwal, BB (2009). Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11: 495-510.
35. Anand, P, Thomas, SG, Kunnumakkara, AB, Sundaram, C, Harikumar, KB, Sung, B et al. (2008). Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76: 1590-1611.
36. Dhillon, N, Aggarwal, BB, Newman, RA, Wolff, RA, Kunnumakkara, AB, Abbruzzese, JL et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499.
37. Anand, P, Sundaram, C, Jhurani, S, Kunnumakkara, AB and Aggarwal, BB (2008). Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267: 133-164.
38. Aggarwal, BB and Harikumar, KB (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41: 40-59.
39. Anand, P, Kunnumakkara, AB, Newman, RA and Aggarwal, BB (2007). Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818.
40. Mulik, R, Mahadik, K and Paradkar, A (2009). Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: physicochemical characterization and stability study. Eur J Pharm Sci 37: 395-404.
41. Shaikh, J, Ankola, DD, Beniwal, V, Singh, D and Kumar, MN (2009). Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37: 223-230.
42. Narayanan, NK, Nargi, D, Randolph, C and Narayanan, BA (2009). Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125: 1-8.
43. Yadav, VR, Suresh, S, Devi, K and Yadav, S (2009). Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol 61: 311-321.
44. Cui, J, Yu, B, Zhao, Y, Zhu, W, Li, H, Lou, H et al. (2009). Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm 371: 148-155.
45. Chen, C, Johnston, TD, Jeon, H, Gedaly, R, McHugh, PP, Burke, TG et al. (2009). An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm 366: 133-139.
46. Choi, HS, Ipe, BI, Misra, P, Lee, JH, Bawendi, MG and Frangioni, JV (2009). Tissueand organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 9: 2354-2359.
47. Bisht, S, Feldmann, G, Soni, S, Ravi, R, Karikar, C, Maitra, A et al. (2007). Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 5: 3.
48. Li, L, Braiteh, FS and Kurzrock, R (2005). Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104: 1322-1331.
49. Li, J, Jiang, Y, Wen, J, Fan, G, Wu, Y and Zhang, C (2009). A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomed Chromatogr 23: 1201-1207.
50. Epstein, J, Sanderson, IR and Macdonald, TT (2010). Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr (epub ahead of print).